100 related articles for article (PubMed ID: 1835549)
1. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study.
Sindrup SH; Grodum E; Gram LF; Beck-Nielsen H
Ther Drug Monit; 1991 Sep; 13(5):408-14. PubMed ID: 1835549
[TBL] [Abstract][Full Text] [Related]
2. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
Sindrup SH; Gram LF; Brøsen K; Eshøj O; Mogensen EF
Pain; 1990 Aug; 42(2):135-144. PubMed ID: 2147235
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
4. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms.
Sindrup SH; Gram LF; Skjold T; Frøland A; Beck-Nielsen H
Clin Pharmacol Ther; 1990 Apr; 47(4):509-15. PubMed ID: 2328559
[TBL] [Abstract][Full Text] [Related]
5. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline.
Kuhs H; Schlake HP; Rolf LH; Rudolf GA
Acta Psychiatr Scand; 1992 May; 85(5):364-9. PubMed ID: 1534961
[TBL] [Abstract][Full Text] [Related]
6. Paroxetine: pharmacokinetic and antidepressant effect in the elderly.
Lundmark J; Scheel Thomsen I; Fjord-Larsen T; Manniche PM; Mengel H; Møller-Nielsen EM; Pauser H; Wålinder J
Acta Psychiatr Scand Suppl; 1989; 350():76-80. PubMed ID: 2530794
[TBL] [Abstract][Full Text] [Related]
7. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
[TBL] [Abstract][Full Text] [Related]
8. Plasma beta-endorphin is not affected by treatment with imipramine or paroxetine in patients with diabetic neuropathy symptoms.
Sindrup SH; Bach FW; Gram LF
Clin J Pain; 1992 Jun; 8(2):145-8. PubMed ID: 1385995
[TBL] [Abstract][Full Text] [Related]
9. A review of the metabolism and pharmacokinetics of paroxetine in man.
Kaye CM; Haddock RE; Langley PF; Mellows G; Tasker TC; Zussman BD; Greb WH
Acta Psychiatr Scand Suppl; 1989; 350():60-75. PubMed ID: 2530793
[TBL] [Abstract][Full Text] [Related]
10. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
J Affect Disord; 1990 Apr; 18(4):289-99. PubMed ID: 2140382
[TBL] [Abstract][Full Text] [Related]
11. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Tulloch IF; Johnson AM
J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine in the treatment of depression--a randomized comparison with amitriptyline.
Laursen AL; Mikkelsen PL; Rasmussen S; le Fèvre Honoré P
Acta Psychiatr Scand; 1985 Mar; 71(3):249-55. PubMed ID: 3157296
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine plasma levels: lack of correlation with efficacy or adverse events.
Tasker TC; Kaye CM; Zussman BD; Link CG
Acta Psychiatr Scand Suppl; 1989; 350():152-5. PubMed ID: 2530776
[No Abstract] [Full Text] [Related]
14. Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection.
Brett MA; Dierdorf HD; Zussman BD; Coates PE
J Chromatogr; 1987 Aug; 419():438-44. PubMed ID: 2959675
[No Abstract] [Full Text] [Related]
15. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
Dechant KL; Clissold SP
Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic dose titration study in adult and elderly depressed patients.
Hebenstreit GF; Fellerer K; Zöchling R; Zentz A; Dunbar GC
Acta Psychiatr Scand Suppl; 1989; 350():81-4. PubMed ID: 2530795
[No Abstract] [Full Text] [Related]
17. A comparison of paroxetine, imipramine and placebo in depressed out-patients.
Dunbar GC; Cohn JB; Fabre LF; Feighner JP; Fieve RR; Mendels J; Shrivastava RK
Br J Psychiatry; 1991 Sep; 159():394-8. PubMed ID: 1835664
[TBL] [Abstract][Full Text] [Related]
18. An overview of paroxetine.
Boyer WF; Feighner JP
J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
20. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities.
Saletu B; Frey R; Krupka M; Anderer P; Grünberger J; See WR
Sleep; 1991 Oct; 14(5):439-47. PubMed ID: 1836894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
